FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1
FORXIGA® is the only SGLT2 inhibitor with UK-specific real world evidence from the CPRD database3
Patients in the UK initiated on FORXIGA® with metformin:
- Experienced an average reduction in HbA1c of more than 1.1 % when treated for 6 months or longer with FORXIGA®3
- Results from real-world evidence studies may not necessarily relate to the effect of the intervention/treatment alone. Results should be interpreted in the context of randomised controlled trial findings.
What is CPRD?
- CPRD stands for Clinical Practice Research Datalink29
- A governmental, not-for-profit research service, jointly funded by the NHS National Institute for Health Research (NIHR) and the Medicines and Healthcare products Regulatory Agency (MHRA)29
Study inclusion criteria and definition of treatment groups3
*Creatinine clearance < 60 ml/min or estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m2.3
**Insulin ≤3 months prior to FORXIGA® initiation and ≤3 months post FORXIGA® initiation.3